Ramy Farid, Schrödinger CEO (Schrödinger)

Bris­tol My­ers fronts new Schrödinger al­liance with $55M up­front, ex­pand­ing pre­ci­sion on­col­o­gy pro­file

Bris­tol My­ers Squibb has a new R&D part­ner, one to which they’re pay­ing a pret­ty pen­ny to use their dis­cov­ery plat­form.

The phar­ma com­pa­ny is dol­ing out $55 mil­lion up­front to Schrödinger $SD­GR to work on up to five small mol­e­cules, with the po­ten­tial for $2.7 bil­lion in mile­stone pay­ments. Schrödinger’s ini­tial tar­gets in­clude HIF-2 al­pha and SOS1/KRAS for a type of kid­ney can­cer and KRAS-dri­ven can­cers, re­spec­tive­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.